Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.02% to 58.65 CNY per share, with a total market capitalization of 9.844 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - Tianhong Fund has a significant holding in Baipusi, with Tianhong Healthcare A (001558) owning 414,200 shares, representing 5.9% of the fund's net value, making it the seventh-largest holding [2] Group 2 - Tianhong Healthcare A (001558) was established on June 30, 2015, and has a current scale of 251 million CNY, with a year-to-date return of 47.25% and a one-year return of 63.92% [2] - The fund manager, Lü Qiao, has been in position for 265 days, with the fund's total assets amounting to 502 million CNY, achieving a best return of 49.24% and a worst return of 48.82% during his tenure [3]
百普赛斯股价跌5.02%，天弘基金旗下1只基金重仓，持有41.42万股浮亏损失128.42万元